Combination medicament for treatment of neoplastic diseases
CA 2449442 A1 · Owner: Bramm, Erik · Inventors: Hamberg, Karin Jexner; Bramm, Erik; Hjarnaa, Pernille-Julia Vig
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Pharmaceutical composition comprising, as a first anti-neoplastic drug cyanoguanidine IKK inhibitors, and in particular compounds of formula (I) wherein n is 0, 1 or 2; each R independently represents halogen trifluoromethyl, hydroxy, C1-4alkyl, C1-4alkoxy C1-4alkoxycarbonyl, nitro, sulfo, cyano amino or carboxy groups; Q is a straight or branched saturated , or unsaturated C4-20 divalent hydrocarbon radical; X is a bond amino, O, S, carbonyl, carbonylamino, aminocarbonyl oxycarbonyloxy, oxycarbonyl, carbonyloxy aminocarbonyloxy, aminothiocarbonyloxy oxycarbonylamino or , oxythiocarbonylamino; A is di-(C1-4alkoxy)phospinoyloxy C1-4alkoxycarbonyl, C1-4alkoxycarbonylamino C3-12 carbocyclic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 24, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 24, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 24, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.